Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Hanwha Ocean (042660) – Correction of Decision on Acquisition of Shares or Equity Securities of Other Corporations / 2024-12-30

Posted on December 30, 2024August 8, 2026 By K-STOCK Editor No Comments on [Disclosure] Hanwha Ocean (042660) – Correction of Decision on Acquisition of Shares or Equity Securities of Other Corporations / 2024-12-30

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Hanwha Ocean has disclosed a correction updating the target acquisition date to undecided (to be disclosed via amended filing once finalized) regarding its participation in the capital increase of its US subsidiary (Hanwha Ocean USA Holdings Corp.).

📊 [Key Disclosure Details & Financial Highlights]

  • Correction Classification: Corrected Filing (Report)
  • Correction Filing Date: December 30, 2024
  • Original Disclosure Document & Date: Decision on Acquisition of Shares or Equity Securities of Other Corporations (June 14, 2024)
  • Reason for Correction: Change in target acquisition date
  • Major Corrected Items:
    • Target Acquisition Date: December 31, 2024, before correction → Undecided after correction (to be disclosed via amended filing once final completion date is fixed)
  • Target Company Information:
    • Company Name: Hanwha Ocean USA Holdings Corp. (Nationality: USA / CEO: Yeon-Seong Jang)
    • Capital Stock: KRW 1,371 (1 USD / As of Dec 31, 2023, applying exchange rate of KRW 1,371.00/USD)
    • Total Issued Shares: 1,352 shares
    • Relationship: Affiliated Company (100%-owned subsidiary)
    • Main Business: Maritime Service
  • Acquisition Details:
    • Number of Shares to Acquire: 2,650 shares
    • Acquisition Amount: KRW 363,300,000,000 (approx. KRW 363.3B / USD 265,000,000, exchange rate of KRW 1,371.00/USD applied)
    • Total Equity: KRW 4,312,200,000,000 (approx. KRW 4.31T, as of FY2023 consolidated financials)
    • Acquisition Amount to Total Equity Ratio: 8.4%
    • Acquisition Amount to Total Assets Ratio: 2.6% (Based on FY2023 consolidated total assets of KRW 13.94T)
    • Owned Shares & Equity Ratio Post-Acquisition: 4,002 shares (100.0%)
    • Method of Acquisition: Participation in Capital Increase by Shareholder Allocation (Cash acquisition)
    • Purpose of Acquisition: Participation in capital increase to secure investment capital
    • Board Resolution Date: June 14, 2024 (All 5 Outside Directors attended)
  • Other Important Notes:
    • Target entity is a newly incorporated company in 2023
    • Target acquisition date is currently undecided and will proceed according to business progress; a corrected disclosure will be filed once the final end date is fixed
    • Related Disclosures: June 14, 2024 (Decision on Acquisition of Shares or Equity Securities of Other Corporations & Decision on Capital Increase by Subsidiary)

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Target Acquisition Date Revision and Subsequent Filings

This correction disclosure notifies the market that the target acquisition date for the US subsidiary’s shares was changed to undecided, with an amended filing scheduled once the final completion date is confirmed. Verifying whether a subsequent corrected disclosure is filed with the finalized acquisition date in accordance with project progress is essential for tracking the actual execution status of the initially disclosed equity investment. Related details can be verified in upcoming official regular filings, including Quarterly, Half-Yearly, and Annual Reports.

📢 Disclaimer & Fact Source

Source: This content was structured and newly written based on officially submitted data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Disclaimer: This material is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Shipbuilding

Post navigation

Previous Post: [Disclosure] Hanwha Ocean (042660) – Correction of Decision on Acquisition of Shares or Equity Securities of Other Corporations by Subsidiary / 2024-12-30
Next Post: [Disclosure] Hanwha Ocean (042660) – Correction of Decision on Capital Increase by Subsidiary / 2024-12-30

Related Posts

[Disclosure] Jusung Engineering(036930) – Investor Relations (IR) Presentation / 2023-12-06 Semiconductors
[Disclosure] Hanwha Systems (272210) – Corrected Filing for Acquisition of Shares in Subsidiary Hanwha Systems USA Corp. (Expected Date Revised to Dec 22, 2025) Disclosures
[Disclosure] Wonik IPS (240810) – Advance Notice of Financial Results / 2024-02-07 Semiconductors
[Disclosure] Hanwha Ocean (042660) – Correction of Decision on Monetary Loan / 2025-01-08 Disclosures
[Disclosure] Jusung Engineering (036930) – Notice on Market Actions for Stock Futures and Options (Notice on Stock Futures Market Actions Due to Corporate Spin-off) / 2024-10-10 Semiconductors
[Disclosure] Hanwha Ocean (042660) to Hold Corporate Earnings Conference (IR) for Q1 2024 Financial Results on April 24 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme